Disturbed Matrix Metalloproteinase Pathway in Both Age-Related Macular Degeneration and Alzheimer's Disease

Area of Science:

• Biochemistry
• Neuroscience
• Ophthalmology

Background:

• Abnormal protein deposits, such as beta-amyloid, accumulate in aging tissues like the brain and Bruch's membrane.
• Matrix metalloproteinases (MMPs) are crucial for degrading these protein deposits.
• In aging Bruch's membrane and age-related macular degeneration (AMD), MMPs become less effective due to polymerization and aggregation, forming the MMP Pathway.

Purpose of the Study:

• To investigate the presence and function of the MMP Pathway in brain tissue.
• To determine if the MMP Pathway contributes to beta-amyloid degradation in Alzheimer's disease (AD).

Main Methods:

• Zymography was used to detect high molecular weight MMP species (HMW1, HMW2) and LMMC aggregates.
• Centrifugation and gel filtration were employed to quantify the distribution of bound and free MMP species.

Main Results:

• The MMP Pathway was identified in brain tissue, similar to its presence in ocular tissues.
• In Alzheimer's disease (AD) samples, a significant reduction in bound HMW1 and pro-MMP9 species was observed (p < 0.05).
• Abnormalities in the MMP Pathway in AD reduced the overall degradation capacity of the MMP system.

Conclusions:

• The MMP Pathway exists in both brain and ocular tissues.
• Dysfunction of the MMP Pathway in the brain may impair beta-amyloid degradation, contributing to Alzheimer's disease (AD).
• Abnormalities in the MMP Pathway could underlie anomalous deposits in both AD and AMD.